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sensitivity. In contrast, low ghrelin level
inhibited while high levels stimulated in-
sulin from mouse islets (Salehi et al.,
2004). Furthermore, Heijboer et al.
(2006) reported that ghrelin treatment
hampered insulin’s ability to suppress
glucose production and increased glu-
cose disposal, actions opposite to the
current study. These discrepancies may
arise from additional effects of ghrelin
treatment on endogenous ghrelin levels,
glucocorticoids, and various hormones.
Overall, the studies provide compelling
evidence that ghrelin has unique dual
effects on glucose homeostasis, at least
in a genetic model. Ghrelin antagonism
may be a new approach for treating type
2 diabetes by increasing insulin secretion
and enhancing peripheral insulin action.
The challenge is to ascertain if these
results in rodents can be translated to
patients.
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Figure 1. Model for actions of ghrelin on glucose homeostasis
Based on deletion of ghrelin, it appears ghrelin acts on pancreatic b cells to inhibit insulin production and
secretion, possibly by increasing UCP2. Ghrelin also inhibits glucose uptake in muscle and adipose tissue
and stimulates glucose production by the liver. Pharmacological stimulation of appetite by ghrelin was not
supported in this genetic model. Ghrelin did not affect feeding or weight.
P R E V I E W SFSH versus estrogen: Who’s guilty of breaking
bones?
Bone loss after menopause or gonadectomy has been attributed to the drop in estrogen levels. A recent paper (Sun et al.,
2006) challenges this view by showing that the pituitary hormone FSH, previously thought to target only the gonads, also
acts on osteoclasts to activate bone resorption. In conjunction with genetic studies, these data raise the possibility that
FSH, independent of estrogen, causes hypogonadal bone loss.In a provocative paper recently published
in Cell (Sun et al., 2006), Drs. Zaidi and302Blair’s groups report observations from
which they conclude that high-circulatingfollicular-stimulating hormone (FSH), not
declining levels of estrogen, causesCELL METABOLISM : MAY 2006
P R E V I E W SFigure 1. Classical paradigms of hormonal control of bone mass
A) Under normal gonadal function, GnRh from the hypothalamus stimulates the pituitary to secrete FSH (and
LH) to target the follicles in the ovary and induce the secretion of estrogen. Estrogen then targets bone cells,
both osteoblasts to form bone and osteoclasts to reduce bone resorption, thereby maintaining bone mass.
In addition, inhibins produced in the ovary feedback the hypothalamic-pituitary axis to reduce GnRH and
FSH (and LH) production.
B) Under decreased gonadal function (menopause), estrogen production is reduced, leading to a net decrease
in bone formation and an increase in bone resorption with net decrease in bone mass as well as an increase in
GnRH, FSH, and LH.hypogonadal bone loss. This happens
because FSH directly regulates osteo-
clasts and bone resorption. These two
conclusions represent a major shift in
two paradigms (Figure 1): first, FSH, like
LH, was thought to target exclusively
cells in the gonads, and second, de-
creasing estrogen levels have always
been thought to be the cause for post-
menopausal bone loss.
Indeed, it is considered self-evident
that postmenopausal osteoporosis is
directly linked to the declining levels of
estrogen (Riggs et al., 2002). After all,
acute estrogen depletion following go-
nadectomy in women or in animal
models rapidly induces bone loss; this
can be prevented or reversed by treat-
ment with estrogen (Riggs et al., 2002).
Estrogen’s role is not limited to females:
in males, some androgen effects on
bone mass are dependent on aromatiza-
tion to estrogens, such that estrogen
receptor or aromatase deficiency in
men leads to bone loss (Smith et al.,
1994; Hermann et al., 2002).
Few in the bone field paid particular at-
tention to another aspect of menopauseCELL METABOLISM : MAY 2006that accompanies or even precedes the
decline in ovarian function and the drop
in the levels of estrogen: FSH, the pitui-
tary hormone responsible for the stimula-
tion of granulosa cells in the ovary (or
Sertoli cells in the testis) to produce suf-
ficient amountsof sex hormones, reaches
sky-high levels (Figure 2). This may pos-
sibly be in an attempt to compensate
the declining hormonal production by
less-responsive ovary (or testicular) cells.
The current work was prompted by
earlier observations that, while ovari-
ectomy causes profound bone loss, the
response is blunted in hypophysecto-
mized rats (Yeh, 1996, 1997). Further-
more, recent clinical studies have shown
a stronger correlation for FSH levels than
estrogen with bone turnover or bone
mass in postmenopausal or amenorrheic
women (Devleta et al., 2004; Sowers
et al., 2006), or with bone mass gains af-
ter estrogen therapy (Kawai et al., 2004),
leading to the hypothesis that FSH may
directly affect bone metabolism.
The latest paper includes observations
made in FSH or FSH receptor null mice.
Deletion of FSH receptors (FSHR) leads,as expected, to an absence of endoge-
nous stimulation of estrogen production
by the ovary and an atrophy of the repro-
ductive organs (hypogonadism). This
lack of target organ response leads to
a marked increase in FSH levels. These
changes in FSH, together with low estro-
gen, mimic in part the situation at meno-
pause or after gonadectomy. According
to the existing paradigm (Figure 1), one
would have therefore expected a rapid
decrease in bone mass. Unexpectedly,
however, bone mass remained unaf-
fected in these mice, despite low estro-
gen levels, although measurement of
these is not reported in the manuscript.
Moreover, whereas low estrogen
levels are associated with a marked in-
crease in bone turnover and specifically
an increase in bone resorption (Fig-
ure 1B), this was not apparent in the
absence of FSHR in vivo. This lack of
osteoclast response could explain the
lack of induced bone loss. Indeed,
ex vivo studies indicated that osteo-
clastogenesis (the formation of bone re-
sorbing cells) and bone resorption were
markedly decreased in the absence of a
receptor for FSH. Thus, in the absence
of FSHR, low estrogen levels are not suf-
ficient to induce the increase in bone
turnover and bone resorption, which is
characteristic of early menopause and
leads to bone loss and osteoporosis.
The authors then went on to examine
the changes in bone homeostasis that
would occur in the absence of the
hormone (FSH) rather than its receptor.
Surprisingly, again, despite severe hypo-
gonadism, FSHb null homozygous mice
also failed to lose bone and even gained
some (Figure 3A), despite low levels of
estrogen (data not shown). The most
compelling set of data was however
obtained in mice haploinsufficient for
FSHb. In these mice, the circulating levels
of FSH are, as expected, decreased by
about 50% but this is high enough to en-
sure a maintenance of normal levels of
circulating estrogen. Yet, despite normal
estrogen levels, these mice showed a de-
crease in bone resorption and a moderate
increase, not decrease, in bone mass.
Taken together, these data suggested
that FSH, acting via its cognate receptor,
was capable of regulating osteoclasto-
genesis and bone resorption, indepen-
dent of estrogen levels. But is it a direct
effect of FSH on osteoclasts or their
precursors? To answer this crucial ques-
tion, the authors then tested osteoclast303
P R E V I E W Sprecursors, as well as human and murine
mature osteoclasts. They show that oste-
oclasts express FSHR at their surface and
are directly stimulated by FSH in vitro,
via the Gi2a activation of MEK/Erk, NfkB
and Akt, a well-established osteoclast-
activating pathway (Boyle et al., 2003).
Importantly, and in contrast with estro-
gen, no receptors for FSH were found in
the bone forming cells (osteoblasts).
If the presence of FSHR on osteoclasts
and their direct responsiveness to FSH
are convincingly established, the conclu-
sion that hypogonadal bone loss is
caused by FSH, independent of estrogen,
might be somewhat premature in the ab-
sence of some key control experiments.
Figure 2. Hormonal changes at menopause
As menopause approaches, levels of estrogen decline
and levelsofFSH (andLH) increasemarkedly. Inestab-
lished menopause, circulating levels of estrogen are
low, and levels of FSH remain high for several years.304First, it bears repeating that simply cor-
recting estrogen levels is sufficient to pre-
vent or treat low bone mass in patients
and in animal models. It is therefore pos-
sible that residual, albeit low, levels of es-
trogen in the FSHR null mice were suffi-
cient to protect against bone resorption
and maintain bone mass. As the levels of
estrogen (and androgen) in these mice
are not reported, this possibility is difficult
to verify.
Indeed, estrogen receptor (ER) knock-
out mice provide evidence that sex hor-
mones can regulate bone mass indepen-
dent of FSH: double ER null female mice
have a low bone mass (Sims et al., 2002),
despite normal levels of FSH (Couse
et al., 2003). Furthermore, the surprisingly
normal bone mass maintained by ERa
null mice does not reflect an irrelevance
of ERa; rather, in the absence of ERa cir-
culating levels of androgen are markedly
increased in both males and females
(Couse and Korach, 1999; Sims et al.,
2002), which prevent bone loss via the
androgen receptor (Sims et al., 2003).
These studies therefore show a critical
role for estrogen and androgen receptors
in the maintenance of bone mass, despite
unchanged FSH levels. Furthermore,
luteinizing hormone (LH) levels, notFigure 3. Shifted paradigm of hormonal control of bone mass
A) In the absence of FSH (or FSHR), estrogen levels are low, but bone resorption, normally directly regulated
by FSH, decreases so much that bone mass increases, despite low levels of estrogen.
B) Under decreased gonadal function (menopause), estrogen production is reduced, with reduced net-bone
formation and increased bone resorption because of direct effects of FSH on osteoclasts; this leads to
a marked decrease in bone mass.reported in Sun et al. (2006), could well
have induced an increase in androgens.
Indeed, Danilovich et al. (2000) measured
androgen levels in FSHR knockout mice
and found them markedly increased;
this could potentially explain most of
the changes in bone mass reported by
Zaidi’s and Blair’s groups.
It should also be noted that showing
that a decrease in FSH increases (mod-
estly) bone mass does not automatically
imply the converse, i.e., that an increase
in FSH would lead to a decrease in bone
mass. It will be interesting to test this
in vivo, combining increased FSH with
antiestrogen, for example, to more defini-
tively address whether FSH has ‘‘estro-
gen-independent’’ effects on bone. More-
over, gonadectomies in female and male
FSH mutant mice, and treatment with es-
trogen, androgen, and their respective
antagonists will be necessary to answer
the essential question of whether ovariec-
tomystill leads toan increase inbone turn-
over and bone loss in the absence of FSH
orFSHR.Afterall, a decrease in resorption
in the absence of FSH with normal estro-
gen levels, as in the FSH haploinsufficient
mice, does not directly demonstrate that
the increase in bone resorption that fol-
lows ovariectomy is FSH dependent.
Until such experiments are performed,
it would be safer to conclude from this
exciting report that both FSH and estro-
gen play key roles in the response of
bone to menopause or gonadectomy
(Figure 3B). The paper by Zaidi and
Blair’s groups goes a long way in estab-
lishing that FSH may contribute directly
to the regulation of bone resorption and,
thereby, bone mass, and this paper will
doubtless trigger a myriad of follow-on
investigations testing the hypothesis.
The study certainly suggests that FSH
may participate in the pathophysiological
process of bone loss in osteoporosis,
a thought-provoking finding. There is still
some way to go, however, before defini-
tively concluding that high-circulating
FSH causes hypogonadal bone loss.
Roland Baron1
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